

Koji Kato, MD. PhD.
Associate Professor

Department of Hematology, Oncology and Cardiovascular medicine
Kyushu University Hospital

Department of Medicine and Biosystemic Science,
Kyushu University Graduate School of Medical Science

3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka, 812-8582 Japan

JUL 7, 2023

EDUCATION

1989 - 1995 Kyushu University School of Medicine, Japan
5 / 1995 M.D. Kyushu University School of Medicine
3 / 2005 Ph.D. (Dr. of Medical Science), Kyushu University

RESIDENCY TRAINING

5 / 1995 - 5 / 1996 Resident, Miyazaki Prefectural Hospital, Miyazaki
5 / 1996 -11/ 1996 Resident, Department of Internal Medicine, Yamaguchi Red Cross Hospital, Yamaguchi
11/1996 - 5 / 1997 Resident, First Department of Internal Medicine, Kyushu University Hospital, Fukuoka
5 / 1997 - 5 / 1998 Resident, Kitakyushu Municipal Medical Center, Fukuoka

FELLOWSHIPS

9 / 2000 - 5 / 2002 Clinical Fellow, First Department of Internal Medicine, Kyushu University Hospital
5 / 2002 - 3 / 2006 Clinical Fellow, The Department of Hematology, Hamanomachi General Hospital

RESEARCH POSITION

5 / 1998 - 8 / 2000 Research Fellow, First Department of Internal Medicine, Kyushu University
4 / 2006 - 9 / 2009 Research Fellow, Blood and Marrow Transplantation Program,
University of Michigan Comprehensive Cancer Center, MI, USA

PRESENT POSITION

10 / 2009 - 3 / 2017 Assistant Professor, Department of Medicine and Biosystemic Science,
Kyushu University Hospital, Japan
4 / 2017 - 9 / 2018 Lecuture, Department of Hematology, Oncology and Cardiovascular medicine,
Kyushu University Hospital
10 /2019 - 3 / 2022 Clinical Associate Professor, Department of Hematology, Oncology and Cardiovascular

medicine, Kyushu University Hospital
4 /2022 - Present Associate Professor, Department of Medicine and Biosystemic Science, Kyushu University
Graduate School of Medical Science

BOARD CERTIFICATION

Japanese Board of Internal Medicine: # 14594, # 7183
Japanese Board of Hematology: # 191078, # 192078
Japanese Board of Hematopoietic Cell Transplantation: # 251046

MEMBERSHIP OF ACADEMIC SOCIETIES

The Japanese Society of Internal Medicine, The Japanese Society of Hematology, The Japanese Society of Clinical Hematology, The Japan Society for Hematopoietic Cell Transplantation, The Japan Society of Transfusion Medicine and Cell Therapy, The Japanese Society for Lymphoreticular Tissue Research, The Japanese Society for Immunology, The American Society of Hematology

Bibliography

【Original article】

1. Shimoda K, **Kato K**, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S, Shibata S, Asano Y, Gondo H, Sekiguchi K, Nakayama K, Nakayama T, Okamura T, Okamura S, Niho Y, and Nakayama K. Tyk2 Plays a Restricted Role in IFN Signaling, Although It Is Required for IL-12-Mediated T Cell Function. *Immunity* 2000; 13: 561-571.
2. Shimoda K, Tsutsui H, Aoki K, **Kato K**, Matsuda T, Numata A, Takase K, Yamamoto T, Nukina H, Hoshino T, Asano Y, Gondo H, Okamura T, Okamura S, Nakayama K, Nakanishi K, Niho Y, Harada M. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. *Blood*. 2002; 99: 2094-2099.
3. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, **Kato K**, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: Comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. *Bone Marrow Transplant*. 2002; 29: 599-606.
4. Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K, Tamiya S, **Kato K**, Takase K, Imamura R, Yamamoto T, Miyamoto T, Nagafuji K, Gondo H, Nagafuchi S, Nakayama K, Harada M. Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. *J Immunol*. 2002; 169: 4707-4711.
5. **Kato K**, Kamezaki K, Shimoda K, Numata A, Haro T, Aoki K, Ishikawa F, Takase K, Ariyama H, Matsuda T, Miyamoto T, Nagafuji K, Gondo H, Nakayama K, Harada M. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. *Br J Haematol*. 2003; 123: 528-535.

6. Kamezaki K, Shimoda K, Numata A, Aoki K, **Kato K**, Takase K, Nakajima H, Ihara K, Haro T, Ishikawa F, Imamura R, Miyamoto T, Nagafuji K, Gondo H, Hara T, Harada M. The lipocalin 24p3, which is an essential molecule in IL-3 withdrawal-induced apoptosis, is not involved in the G-CSF withdrawal-induced apoptosis. *Eur J Haematol.* 2003; 71: 412-417.
7. Nagafuji K, Aoki K, Henzan H, **Kato K**, Miyamoto T, Eto T, Nagatoshi Y, Ohba T, Obama K, Gondo H, Harada M. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. *Bone Marrow Transplant.* 2004; 34: 909-914.
8. Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, Takase K, Aoki K, Henzan H, Nagafuji K, Miyamoto T, Ishikawa F, Shimoda K, Inaba S, Tsukamoto H, Horiuchi T, Nakashima H, Otsuka T, **Kato K**, Kuroiwa M, Higuchi M, Shibuya T, Kamimura T, Kuzushima K, Tsurumi T, Kanda Y, Harada M. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation. *Int J Hematol.* 2004; 80:441-448.
9. Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, **Kato K**, Miyamoto T, Yamashita Y, Oshima Y, Nakajima H, Iwama A, Aoki K, Takase K, Gondo H, Mano H, Harada M. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway. *J Biol Chem.* 2005; 280:12621-12629.
10. Imamura R, Miyamoto T, Yoshimoto G, Kamezaki K, Ishikawa F, Henzan H, **Kato K**, Takase K, Numata A, Nagafuji K, Okamura T, Sata M, Harada M, Inaba S. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. *J Immunol.* 2005; 175: 2647-2654.
11. Yoshimoto G, Nagafuji K, Miyamoto T, Kinukawa N, Takase K, Eto T, **Kato K**, Hayashi S, Kamimura T, Ohno Y, Taniguchi S, Harada M. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2005; 36: 977-983.
12. Hashiguchi M, Okamura T, Yoshimoto K, Ono N, Imamura R, Yakushiji K, Ogata H, Seki R, Otsubo K, Oku E, Kuroiwa M, Higuchi M, **Kato K**, Taniguchi S, Gondo H, Shibuya T, Nagafuji K, Harada M and Sata M. Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2005; 36:1071-1075.
13. Muta T, Tsuruta N, Seki Y, Ota R, Suzuki S, Shibata N, **Kato K**, Eto T, Gondo H, Arakawa Y. A nosocomial outbreak due to novel CTX-M-2-producing strains of *Citrobacter koseri* in a hematological ward. *Jpn J Infect Dis.* 2006; 59: 69-71.
14. **Kato K**, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S, Morishima Y, Kodera Y, Harada M for the Japan marrow donor program. Allogeneic bone marrow transplantation from unrelated HTLV-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan marrow donor program. *Biol Blood Marrow Transplant.* 2007; 13: 90-99.
15. Kamezaki K, Kikushige Y, Numata A, Takase K, Henzan H, Aoki K, **Kato K**, Nonami A, Kamimura T, Arima F, Takenaka K, Harada N, Fukuda T, Hayashi S, Ohno Y, Eto T, Harada M, Nagafuji K. Rituximab Does Not Compromise the Mobilization and Engraftment of Autologous Peripheral Blood Stem Cells in Diffuse-Large B-cell

Lymphoma. Bone Marrow Transplant. 2007; 39: 523-527.

16. Khaled Y, **Kato K**, Janakiraman N, Ferrara JLM, Mineishi S. Early Relapses Do Not Impact Survival after Autologous Stem Cell Transplantation in African Americans with Multiple Myeloma. Bone Marrow Transplant. 2007; 39: 727-728.

17. Muta T, **Kato K**, Gondo H, Oku S, Okeda A, Kamo M, Nawata R, Takase K, Arima F, Shibuya T, Eto T. The consequences of tacrolimus blood concentrations during the four weeks following marrow transplantation from an unrelated donor: a single-center experience. Jpn J Cancer Chemother. 2008; 35: 99-104.

18. Khaled Y, Abidi MH, Janakiraman N, **Kato K**, Levine JE, Reddy P, Medina M, Peres E, Hanbali A, Mineishi S. Outcomes after auto-SCT in African Americans with multiple myeloma. Bone Marrow Transplant. 2009;43: 845-851.

19. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, **Kato K**, Mineishi S. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant. 2009; 44: 579-583.

20. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, **Kato K**, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M and Eto T for the Fukuoka Blood and Marrow Transplantation Group. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010; 45: 311-316.

21. **Kato K**, Cui S, Kuick R, Mineishi S, Hexner E, Ferrara JL, Emerson SG, Zhang Y. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8(+) T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant. 2010; 16: 751-771.

22. Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N, **Kato K**, Takenaka K, Iwasaki H, Harada N, Abe Y, Teshima T, Akashi K. High incidence of HHV6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16: 1596-1602.

23. Zhang Y, Sandy AR, Wang J, Radojic V, Shan GT, Tran IT, Friedman A, **Kato K**, He S, Cui S, Hexner E, Frank DM, Emerson SG, Pear WS, Maillard I. Notch signaling is a critical regulator of allogeneic CD4+ T cell responses mediating graft-versus-host disease. Blood. 2011; 117: 299-308.

24. He S*, **Kato K***, Jiang J, Wahl DR, Mineish S, Fisher EM, Murasko DM, Glick GD, Zhang Y. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS ONE. 2011; 6(5); e20107. **(*Equal contribution to this work)**

25. Mori Y, Miyawaki K, **Kato K**, Takenaka K, Iwasaki H, Harada N, Miyamoto T, Akashi K, Teshima T. Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. Intern Med. 2011; 50: 2149-2155.

26. Mori Y, Miyamoto T, **Kato K**, Kamezaki K, Kuriyama T, Oku S, Takenaka K, Iwasaki H, Harada N, Shiratsuchi M, Abe Y, Nagafuji K, Teshima T, Akashi K. Different risk factors related to adenovirus- or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18: 458-65.

27. Mori Y, Teshima T, Kamezaki K, **Kato K**, Takenaka K, Iwasaki H, Miyamoto T, Nagafuji K, Eto T, Akashi K.

Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. *Bone Marrow Transplant*. 2012; 47: 1075-81.

28. He S*, Wang J*, **Kato K***, Xie F, Varambally S, Mineishi S, Kuick R, Mochizuki K, Liu Y, Nieves E, Mani RS, Chinnaiyan AM, Marquez VE, Zhang Y. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. *Blood*. 2012; 119: 1274-82. **(*Equal contribution to this work)**

29. Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, Nishi Y, Henzan H, **Kato K**, Harada N, Eto T, Miyamoto T, Teshima T, Akashi K. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. *Int J Hematol*. 2012; 96: 94-100.

30. Mori Y, Miyamoto T, Kamezaki K, **Kato K**, Kikushige Y, Takashima S, Urata S, Shimoda S, Shimono N, Takenaka K, Iwasaki H, Nagafuji K, Teshima T, Akashi K. Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era. *Am J Hematol*. 2012; 87 :828-30.

31. Ishida T, Hishizawa M, **Kato K**, Tanosaki R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y, Hidaka M, Akashi K, Uike N, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishiyama T, Utsunomiya A. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. *Blood*. 2012; 120: 1734-41.

32. Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, Iwasaki H, Kamimura T, Eto T, Nagafuji K, Teshima T, **Kato K**, Akashi K. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. *Blood*. 2013; 121: 840-8.

33. Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, **Kato K**, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG). Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. *Intern Med*. 2013; 52: 63-70.

34. Uchida M, Ikesue H, **Kato K**, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Egashira N, Akashi K, Oishi R. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. *Am J Health Syst Pharm*. 2013; 70: 343-9.

35. Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Henzan T, **Kato K**, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG). Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma. *Rinsho Ketsueki*. **[in Japanese]** 2013; 54:109-16.

36. Watanabe H, Ikesue H, Tsujikawa T, Nagata K, Uchida M, Suetsugu K, Egashira N, Muta T, **Kato K**, Takenaka K, Ohga S, Matsushima T, Shiratsuchi M, Miyamoto T, Teshima T, Akashi K, Oishi R. Decrease in venous irritation by adjusting the concentration of injected bendamustine. *Biol Pharm Bull*. 2013; 36: 574-8.

37. Daisaki H, Tateishi U, Terauchi T, Tatsumi M, Suzuki K, Shimada N, Nishida H, Numata A, **Kato K**, Akashi K, Harada M. Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma. *Ann Nucl Med*. 2013; 27: 225-32.
38. Mochizuki K, Xie F, He S, Tong Q, Liu Y, Mochizuki I, Guo Y, **Kato K**, Yagita H, Mineishi S, Zhang Y. Delta-Like Ligand 4 Identifies a Previously Uncharacterized Population of Inflammatory Dendritic Cells That Plays Important Roles in Eliciting Allogeneic T Cell Responses in Mice. *J Immunol*. 2013; 190: 3772-82.
39. Tamai Y, Hasegawa A, Takamori A, Sasada A, Tanosaki R, Choi I, Utsunomiya A, Maeda Y, Yamano Y, Eto T, Koh KR, Nakamae H, Suehiro Y, **Kato K**, Takemoto S, Okamura J, Uike N, Kannagi M. Potential Contribution of a Novel Tax Epitope-Specific CD4⁺ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation. *J Immunol*. 2013; 190: 4382-92.
40. Uchida M, Ikesue H, Miyamoto T, **Kato K**, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. *Biol Pharm Bull*. 2013; 36: 819-24.
41. Uchida M, **Kato K**, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Shiratsuchi M, Suetsugu K, Nagata K, Egashira N, Akashi K, Oishi R. Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation. *Pharmacotherapy*. 2013; 33: 893-901.
42. Shimoji S, **Kato K**, Eriguchi Y, Takenaka K, Iwasaki H, Miyamoto T, Oda Y, Akashi K, Teshima T. Evaluating the association between histological manifestations of cord colitis syndrome with GVHD. *Bone Marrow Transplant*. 2013; 48: 1249-52.
43. Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, **Kato K**, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. *Int J Hematol*. 2013; 98: 337-45.
44. Ito Y, Miyamoto T, Kamimura T, Takase K, Henzan H, Sugio Y, **Kato K**, Ohno Y, Eto T, Teshima T, Akashi K. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. *Int J Hematol*. 2013; 98: 463-71.
45. Ishida T, Hishizawa M, **Kato K**, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A. Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens: Nationwide Retrospective Study. *Biol Blood Marrow Transplant*. 2013; 19: 1731-9.
46. Muta T, Kamimura T, Miyamoto T, Ohno Y, Henzan T, **Kato K**, Takenaka K, Iwasaki H, Fujisaki T, Eto T, Akashi K. Superiority of tandem autologous stem cell transplantation using high dose melphalan for patients with

multiple myeloma. *International Journal of Myeloma*. 2013; 3: 47–54.

47. Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, **Kato K**, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B-cell lymphoma: a nationwide retrospective study. *Biol Blood Marrow Transplant*. 2014; 20: 684-9.

48. Takashima S, Kamimura T, Miyamoto T, Yoshimoto G, **Kato K**, Ito Y, Muta T, Matsushima T, Shiratsuchi M, Tanimoto K, Takenaka K, Iwasaki H, Teshima T, Akashi K. Comparison of bortezomib, cyclophosphamide, and dexamethasone (VCD) induction with bortezomib and dexamethasone (BD) induction for newly diagnosed symptomatic multiple myeloma. *International Journal of Myeloma*. 2014; 4: 7–12.

49. **Kato K**, Ohno Y, Kamimura T, Kusumoto H, Tochigi T, Jinnouchi F, Kohno K, Kuriyama T, Henzan H, Takase K, Kawano I, Kadowaki M, Nawata R, Muta T, Eto T, Iwasaki H, Ohshima K, Miyamoto T, Akashi K. Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma. *Bone Marrow Transplant*. 2014; 49: 1543-4.

50. Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, **Kato K**, Kamezaki K, Oku S, Henzan H, Takase K, Matsushima T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K, Teshima T. The Use of Oral Beclomethasone Dipropionate in the Treatment of Gastrointestinal Graft-versus-host Disease: The Experience of the Fukuoka Blood and Marrow Transplantation (BMT) Group. *Intern Med*. 2014; 53: 1315-20.

51. Shima T, Miyamoto T, Kikushige Y, Yuda J, Tochigi T, Yoshimoto G, **Kato K**, Takenaka K, Iwasaki H, Mizuno S, Goto N, Akashi K. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. *Exp Hematol*. 2014; 42: 955-65.

52. Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, **Kato K**, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. *Int J Hematol*. 2014; 100: 159-64.

53. **Kato K**, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Nakamae H, Oku E, Murata M, Eto T, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A. Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey. *Biol Blood Marrow Transplant*. 2014; 20: 1968-74.

54. Ito Y, Miyamoto T, Kamimura T, Aoki K, Henzan H, Aoki T, Shiratsuchi M, **Kato K**, Nagafuji K, Ogawa R, Eto T, Iwasaki H, Akashi K. Characteristics of patients with development of large granular lymphocytes expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation. *Clinical Lymphoma Myeloma and Leukemia*. 2015; 15: e47-54.

55. Kako S, Izutsu K, **Kato K**, Kim SW, Mori T, Fukuda T, Kobayashi N, Taji H, Hashimoto H, Kondo T, Sakamaki H, Morishima Y, Kato K, Suzuki R, Suzumiya J; on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation. The role of hematopoietic stem cell transplantation for relapsed and

refractory Hodgkin lymphoma. *Am J Hematol.* 2015; 90: 132-8.

56. Uryu H, Hashimoto D, **Kato K**, Hayase E, Matsuoka S, Ogasawara R, Takahashi S, Maeda Y, Iwasaki H, Miyamoto T, Saijo S, Iwakura Y, Hill GR, Akashi K, Teshima T. α -Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. *Blood.* 2015;125: 3014-23.

57. Takashima S, Miyamoto T, Kamimura T, Yoshimoto G, Yoshida S, Henzan H, Takase K, **Kato K**, Ito Y, Ohno Y, Nagafuji K, Eto T, Teshima T, Akashi K. Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. *Int J Hematol.* 2015; 102: 689-96.

58. Sugio T*, **Kato K***, Aoki T, Ohta T, Saito N, Yoshida S, Kawano I, Henzan H, Kadowaki M, Takase K, Muta T, Miyawaki K, Yamauchi T, Shima T, Takashima S, Mori Y, Yoshimoto G, Kamezaki K, Takenaka K, Iwasaki H, Ogawa R, Ohno Y, Eto T, Kamimura T, Miyamoto T, Akashi K. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. *Biol Blood Marrow Transplant.* 2016; 22: 1608-14. (***Equal contribution to this work**)

59. Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, **Kato K**, Imaizumi Y, Seto M, Ohshima K. PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma. *Blood.* 2016; 128: 1374-81.

60. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, Otsuka E, Henzan H, **Kato K**, Tomoyose T, Yamamoto H, Kurosawa S, Matsuoka K, Yamaguchi T, Fukuda T. Pretransplant anti-CCR4 antibody mogamulizumab against ATLL is associated with significantly increased risks of severe and steroid-refractory GVHD, non-relapse mortality and overall mortality *J Clin Oncol.* 2016; 34: 3426-33.

61. Yurino A, Takenaka K, Yamauchi T, Nunomura T, Uehara Y, Jinnouchi F, Miyawaki K, Kikushige Y, **Kato K**, Miyamoto T, Iwasaki H, Kunisaki Y, Akashi K. Enhanced Reconstitution of Human Erythropoiesis and Thrombopoiesis in an Immunodeficient Mouse Model with Kit (Wv) Mutations. *Stem Cell Reports.* 2016; 7: 425-38.

62. Miyamoto T, Takashima S, **Kato K**, Takase K, Yoshimoto G, Yoshida S, Henzan H, Osaki K, Kamimura T, Iwasaki H, Eto T, Teshima T, Nagafuji K, Akashi K. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation. *Int J Hematol.* 2017; 105: 92-99.

63. Tochigi T, Aoki T, Kikushige Y, Kamimura T, Ito Y, Shima T, Yamauchi T, Mori Y, Yoshimoto G, Kamezaki K, **Kato K**, Takenaka K, Iwasaki H, Akashi K, Miyamoto T. Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs. *Int J Hematol.* 2017; 105: 423-432.

64. Shimoji S, Hashimoto D, Tsujigiwa H, Miyawaki K, **Kato K**, Takahashi S, Ogasawara R, Jiromaru T, Iwasaki H, Miyamoto T, Akashi K, Teshima T. Graft-versus-host disease targets ovary and causes female infertility in mice. *Blood.* 2017; 129: 1216-1225.

65. Kawamoto K, Miyoshi H, Yanagida E, Yoshida N, Kiyasu J, Kozai Y, Morikita T, Kato T, Suzushima H, Tamura S, Muta T, **Kato K**, Eto T, Seki R, Nagafuji K, Sone H, Takizawa J, Seto M, Ohshima K. Comparison of clinicopathological characteristics between T-PLL and PTCL, NOS. *Eur J Haematol.* 2017; 98: 459-466.

66. Miyawaki K, Iwasaki H, Jiromaru T, Kusumoto H, Yurino A, Sugio T, Uehara Y, Odawara J, Daitoku S, Kunisaki Y, Mori Y, Arinobu Y, Tsuzuki H, Kikushige Y, Iino T, **Kato K**, Takenaka K, Miyamoto T, Maeda T, Akashi K. Identification of unipotent megakaryocyte progenitors in human hematopoiesis. *Blood*. 2017; 129: 3332-3343.
67. Minami M, Arita T, Iwasaki H, Muta T, Aoki T, Aoki K, Yamasaki S, Matsushima T, **Kato K**, Takenaka K, Tanimoto K, Kamimura T, Ogawa R, Akashi K, Miyamoto T. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. *Br J Haematol*. 2017; 177: 578-587.
68. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, Ando K, Tsukasaki K, Ishida T, Kobayashi N, Ishizawa K, Tatsumi Y, **Kato K**, Kiguchi T, Ikezoe T, Laille E, Ro T, Tamakoshi H, Sakurai S, Ohtsu T. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. *Int J Hematol*. 2017; 106: 655-665.
69. Fujiwara H, Fuji S, Wake A, **Kato K**, Takatsuka Y, Fukuda T, Taguchi J, Uchida N, Miyamoto T, Hidaka M, Miyazaki Y, Tomoyose T, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. *Bone Marrow Transplant*. 2017; 52: 484-488.
70. Ishida T, Utsunomiya A, Jo T, Yamamoto K, **Kato K**, Yoshida S, Takemoto S, Suzushima H, Kobayashi Y, Imaizumi Y, Yoshimura K, Kawamura K, Takahashi T, Tobinai K, Ueda R. Mogamulizumab for Relapsed Adult T-Cell Leukemia-Lymphoma: Updated Follow-up Analysis of Phase I and II Studies. *Cancer Sci*. 2017; 108: 2022-2029.
71. Shimono J, Miyoshi H, Kato T, Sugio T, Miyawaki K, Kamimura T, Miyagishima T, Eto T, Imaizumi Y, **Kato K**, Nagafuji K, Akashi K, Seto M, Teshima T, Ohshima K. Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. *Oncotarget*. 2017; 9: 1717-1725.
72. Uchida M, Mori Y, Nakamura T, **Kato K**, Kamezaki K, Takenaka K, Shiratsuchi M, Kadoyama K, Miyamoto T, Akashi K. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. *Biol Pharm Bull*. 2017; 40: 1499-1505.
73. Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, **Kato K**, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. *Leukemia*. 2018; 32: 675-684.
74. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group (Investigators/collaborators of Japan: Abe Y, Ando K, Choi I, Fukuhara N, Hatake K, Ichinohe T, Ishizawa K, **Kato K**, Kinoshita T, Maruyama D, Shibayama H, Tobinai K, Tsukamoto N, Uike N,

Yamamoto K). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. *N Engl J Med*. 2018; 378: 331-344.

75. Yoshimitsu M, Tanosaki R, **Kato K**, Ishida T, Choi I, Takatsuka Y, Fukuda T, Eto T, Hidaka M, Uchida N, Miyamoto T, Nakashima Y, Moriuchi Y, Nagafuji K, Miyazaki Y, Ichinohe T, Takanashi M, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2018; 24: 832-839.

76. Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, **Kato K**, Miyahara M, Yujiri T, Oishi N, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein Barr virus positive T/NK-cell lymphoproliferative disorder: Adult patients with chronic active Epstein Barr virus infection-like features. *Haematologica*. 2018; 103: 1018-1028.

77. Shimono J, Miyoshi H, Yoshida N, Kato T, Sato K, Sugio T, Miyawaki K, Kurita D, Sasaki Y, Kawamoto K, Imaizumi Y, **Kato K**, Nagafuji K, Akashi K, Seto M, Teshima T, Ohshima K. Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis. *Am J Surg Pathol*. 2018; 42: 1466-1471.

78. Uchida M, Nakamura T, Hata K, Watanabe H, Mori Y, **Kato K**, Kamezaki K, Takenaka K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K. Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting. *J Pharm Health Care Sci*. 2018; 4: 1.

79. Ogata M, Takano K, Moriuchi Y, Kondo T, Ueki T, Nakano N, Mori T, Uoshima N, Nagafuji K, Yamasaki S, Shibasaki Y, Sakai R, **Kato K**, Choi I, Jo Y, Eto T, Kako S, Oshima K, Fukuda T. Effects of Prophylactic Foscarnet on HHV-6 Reactivation and HHV-6 Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with a Historical Control Group. *Biol Blood Marrow Transplant*. 2018; 24: 1264-1273.

80. Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y, **Kato K**, Shiratsuchi M, Hosohata M, Miyamoto T, Akashi K. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy. *Pharmazie* 2018; 73: 304–308.

81. Mori Y, Yoshimoto G, Nishida R, Sugio T, Miyawaki K, Shima T, Nagasaki Y, Miyake N, Harada Y, Kunisaki Y, Kamezaki K, Numata A, **Kato K**, Shiratsuchi M, Maeda T, Takenaka K, Iwasaki H, Shimono N, Akashi K, Miyamoto T. Gastrointestinal graft-versus-host disease is a risk factor for post-engraftment blood stream infection in allogeneic hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant*. 2018; 24: 2302-2309.

82. Yoshimoto G, Mori Y, **Kato K**, Shima T, Miyawaki K, Kikushige Y, Kamezaki K, Numata A, Maeda T, Takenaka K, Iwasaki H, Teshima T, Akashi K, Miyamoto T. Human Herpes Virus-6-associated Encephalitis/Myelitis mimicking Calcineurin inhibitor induced pain syndrome in allogeneic stem cell transplantation recipients. *Biol Blood Marrow Transplant*. 2018; 24: 2540-2548.

83. Ohmachi K, Ando K, Kinoshita T, Kumagai K, Hatake K, Ishikawa T, Teshima T, **Kato K**, Izutsu K, Ueda E, Nakai K, Kuriki H, Tobinai K. Safety, tolerability and pharmacokinetics of shorter duration of infusion of

obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. *Jpn J Clin Oncol.* 2018; 48: 736-742.

84. Kamiunten A, Sekine M, Kameda T, Akizuki K, Tahira Y, Shide K, Shimoda H, **Kato K**, Hidaka T, Kubuki Y, Shimoda K. Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia. *Hematol Oncol.* 2018; 36: 651-655.

85. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators (Collaborators of Japan: Hatake K, Ishikawa T, Izutsu K, **Kato K**, Kiguchi T, Kobayashi T, Koike M, Ueda Y, Yamamoto G, Yokoyama H). Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. *N Engl J Med.* 2018; 379: 934-947.

86. Sugio T, Miyawaki K, **Kato K**, Sasaki K, Yamada K, Iqbal J, Miyamoto T, Ohshima K, Maeda T, Miyoshi H, Akashi K. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. *Blood Adv.* 2018; 2: 2242-2252.

87. Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, **Kato K**, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2019; 54: 674-680.

88. **Kato K**, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, Takatsuka Y, Fukuda T, Uchida N, Eto T, Nakashima Y, Kondo T, Taguchi J, Miyamoto T, Nakamae H, Ichinohe T, Kato K, Suzuki R, Utsunomiya A. The outcome and characteristics of patients with relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. *Hematol Oncol.* 2019; 37: 54-61.

89. Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, **Kato K**, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. *Br J Haematol.* 2019; 184: 479-483.

90. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group (Collaborators of Japan: **Kato K** et al). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019; 393: 229-240.

91. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C,

Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö,

Salles G, Maziarz RT; JULIET Investigators. (Collaborators of Japan: Teshima T, Izutsu K, **Kato K** et al). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019; 380: 45-56.

92. Uchida M, Nakamura T, Shima T, Mori Y, Yoshimoto G, **Kato K**, Shimokawa M, Hosohata K, Miyamoto T, Akashi K. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy. *Pharmazie*. 2019;74: 250-254.

93. Mori Y, Yoshimoto G, Yuda JI, Hayashi M, Odawara J, Kuriyama T, Sugio T, Miyawaki K, Kamezaki K, **Kato K**, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K. Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation. *Leuk Lymphoma*. 2019; 60: 271-273.

94. Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, **Kato K**; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. *Bone Marrow Transplant*. 2019; 54: 1266-1274.

95. Shimono J, Miyoshi H, Arakawa F, Yamada K, Sugio T, Miyawaki K, Eto T, Miyagishima T, **Kato K**, Nagafuji K, Akashi K, Teshima T, Ohshima K. Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma. *Ann Hematol*. 2019; 98: 1197-1207.

96. Aoki T, Kamimura T, Yoshida S, Mori Y, Kadowaki M, Kohno K, Ishihara D, Urata S, Sugio T, Kamezaki K, **Kato K**, Ito Y, Eto T, Akashi K, Miyamoto T. Safety and seropositivity after live attenuated vaccine in adult patients receiving hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2019; 25: 1576-1585.

97. Fuji S, Kurosawa S, Inamoto Y, Nakano N, Miyazaki Y, Miyashita K, Hidaka M, Eto T, Uchida N, Ito A, Sawayama Y, Miyamoto T, Suzumiya J, Utsunomiya A, Kanda J, Atsuta Y, Fukuda T, **Kato K**, on behalf of Adult T-cell Leukemia-Working Group of Japan Society of Hematopoietic Cell Transplantation. Does an increased probability of graft-versus-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model. *Adv Cell Gene Ther*. 2019; 2: e56.

98. Hori D, Kobayashi R, Fujita N, Suzumiya J, Suzuki R, **Kato K**, Kawata T, Fukuda T, Inoue M, Goto H, Hama A, Iwato K, Okumura H, Eto T, Hashii Y, Atsuta Y, Mitsui T. The effectiveness of busulfan-based conditioning regimens for stem cell transplantation against lymphomas in children, adolescents, and young adults in Japan. *Pediatr Blood Cancer*. 2019; 66: e27918.

99. Kurita D, Miyoshi H, Ichikawa A, **Kato K**, Imaizumi Y, Seki R, Sato K, Sasaki Y, Kawamoto K, Shimono J, Yamada K, Muto R, Kizaki M, Nagafuji K, Tamaru JI, Tokuhira M, Ohshima K. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. *Am J Surg Pathol*. 2019; 43: 869-884.

100. Uchida M, Nakamura T, Watanabe H, **Kato K**, Miyamoto T, Akashi K, Masuda S. Usefulness of medication instruction sheets for sharing information on cancer chemotherapy within the health care team. *Pharmazie*. 2019;74: 566-569.
101. Fukano R, Mori T, Fujita N, Kobayashi R, Mitsui T, **Kato K**, Suzuki R, Suzumiya J, Fukuda T, Shindo M, Maseki N, Shimoyama T, Okada K, Inoue M, Inagaki J, Hashii Y, Sato A, Tabuchi K. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. *Int J Hematol*. 2019; 110: 723-728.
102. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Choi I, Otsuka E, Henzan H, **Kato K**, Nakachi S, Yamamoto H, Fukuda T. Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma. *Bone Marrow Transplant*. 2019; 54: 134-137.
103. Mori Y, Yoshimoto G, Yuda JI, Hayashi M, Odawara J, Kuriyama T, Sugio T, Miyawaki K, Kamezaki K, Kato K, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K. Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation. *Leuk Lymphoma*. 2019; 60: 271-273.
104. **Kato K**, Mori T, Kim SW, Sawa M, Sakai T, Hashimoto H, Taguchi J, Oyake T, Kurahashi S, Imada K, Ohno H, Tanaka J, Ichinohe T, Atsuta Y, Suzuki R, Suzumiya J. Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Bone Marrow Transplant*. 2019; 54: 1515-1517.
105. Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, **Kato K**; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. *Am J Hematol*. 2019; 94: E143-E146.
106. Kato H, **Kato K**, Kim SW, Fukuda T, Mori T, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Taji H, Onizuka M, Kurahashi S, Ichinohe T, Suzumiya J, Suzuki R. Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). *Br J Haematol*. 2019; 186: e170-e175.
107. Yoneshima Y*, **Kato K***, Minami H, Ikeda M, Watanabe H, Yoshimoto G, Miyamoto T, Akashi K, Nakanishi Y, Okamoto I. HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors. *Cancer Sci*. 2020; 111: 3395-3396. (***Equal contribution to this work**)
108. Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, **Kato K**, Katayama N, Yamaguchi M. CD5+ DLBCL Treatment Study Group. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. *Haematologica*. 2020; 105: 2308-2315.

109. Yoshimitsu M, Fuji S, Utsunomiya A, Nakano N, Ito A, Ito Y, Miyamoto T, Suehiro Y, Kawakita T, Moriuchi Y, Nakamae H, Kanda Y, Ichinohe T, Fukuda T, Atsuta Y, **Kato K**. Outcomes of allogeneic hematopoietic stem cell transplantation for ATL with HTLV-1 antibody positive donors: Allo-HCT for ATL from HTLV-1 antibody positive donors. *Biol Blood Marrow Transplant*. 2020; 26: 718-722.
110. Izutsu K, **Kato K**, Kiyoi H, Yamamoto G, Shimada K, Akashi K. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. *Int J Hematol*. 2020; 112: 504-509.
111. Jinnouchi F, Yamauchi T, Yurino A, Nunomura T, Nakano M, Iwamoto C, Obara T, Miyawaki K, Kikushige Y, **Kato K**, Maeda T, Miyamoto T, Baba E, Akashi K, Takenaka K. Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells. *Blood*. 2020; 135: 1661-1672.
112. Tochigi T, Miyamoto T, Hatakeyama K, Sakoda T, Ishihara D, Irifune H, Shima T, **Kato K**, Maeda T, Ito T, Handa H, Akashi K, Kikushige Y. Aromatase is a novel neo-substrate of cereblon responsible for immunomodulatory drugs-induced thrombocytopenia. *Blood*. 2020; 135: 2146-2158.
113. Yamasaki S, Yoshida S, **Kato K**, Choi I, Imamura Y, Kohno K, Henzan H, Tanimoto K, Ogawa R, Suehiro Y, Miyamoto T, Eto T, Ohshima K, Akashi K, Iwasaki H; Fukuoka Blood and Marrow Transplantation Group. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. *Int J Hematol*. 2020; 112: 74-83.
114. Yuda J, Odawara J, Minami M, Muta T, Kohno K, Tanimoto K, Eto T, Shima T, Kikushige Y, **Kato K**, Takenaka K, Iwasaki H, Minami Y, Ohkawa Y, Akashi K, Miyamoto T. TKIs induce alternative spliced BCR-ABL(Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR-ABL. *Cancer Sci*. 2020; 111: 2361-2373.
115. Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, Kawamoto K, Yanagida E, Yamada K, Umeno T, Suzuki T, **Kato K**, Takizawa J, Seto M, Akashi K, Ohshima K. Combination of CD47 and SIRP α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. *Cancer Sci*. 2020; 111: 2608-2619.
116. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group (Collaborators of Japan: **Kato K** et al). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. *N Engl J Med*. 2020; 382: 1800-1810.
117. Goto H, Makita S, **Kato K**, Tokushige K, Fujita T, Akashi K, Izutsu K, Teshima T. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. *Int J Clin Oncol*. 2020; 25: 1736-1743.
118. Henzan H, Takase K, Kamimura T, Mori Y, Yoshimoto G, Iwasaki H, Nagafuji K, Ogawa R, Eto T, Uchida N, Fujisaki T, **Kato K**, Minami M, Kikushige Y, Akashi K, Miyamoto T; Fukuoka Blood & Marrow Transplantation Group (FBMTG). Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. *Int J Hematol*. 2020; 112: 431-432.
119. Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, **Kato K**, Uchida N, Ikegame K, Onizuka M, Matsuoka KI, Doki N, Kawakita T, Onishi Y, Yano S, Fukuda T, Takanashi M, Kanda Y, Atsuta Y, Ogata M; transplant

complications working group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2021; 56: 400-410.

120. Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, Eto T, Hidaka M, Choi I, Miyamoto T, Uchida N, Moriuchi Y, Miyazaki Y, Fukuda T, Ichinohe T, Atsuta Y, **Kato K**. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. *Bone Marrow Transplant.* 2021; 56: 155-166.

121. Izutsu K, Yamamoto K, **Kato K**, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. *Int J Hematol.* 2021; 113: 370-380.

122. Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, Odawara J, Ueno T, Kohno K, Harada T, Yoshimoto G, Takase K, Henzan H, **Kato K**, Ito Y, Kamimura T, Ohno Y, Ogawa R, Eto T, Nagafuji K, Akashi K, Miyamoto T. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. *Bone Marrow Transplant.* 2021; 56: 853-862.

123. Mori Y, Sasaki K, Ito Y, Kuriyama T, Ueno T, Kadowaki M, Aoki T, Sugio T, Yoshimoto G, **Kato K**, Maeda T, Nagafuji K, Akashi K, Miyamoto T; Fukuoka Blood and Marrow Transplantation Group. Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study. *Ann Hematol.* 2021; 100: 197-208.

124. Nakano N, Utsunomiya A, Matsuo K, Yoshida N, Seto M, Ohshima K, Fujiwara H, Fuji S, Takatsuka Y, Ito A, Miyamoto T, Suehiro Y, Nakamae H, Sawayama Y, Yuasa M, Miyazaki Y, Ota S, Imada K, Fukuda T, Ichinohe T, Atsuta Y, **Kato K**. Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT. *Blood Adv.* 2021; 5: 475-486.

125. Sakurai M, Mori T, **Kato K**, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. *Bone Marrow Transplant.* 2021; 56: 1462-1466.

126. Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, **Kato K**, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. *J Clin Oncol.* 2021; 39: 1317-1328.

127. Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, **Kato K**, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H. Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study. *Cancer Sci.* 2021; 112: 2405-2415.

128. Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, **Kato K**, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. *Cancer Sci.* 2021; 112: 2426-2435.
129. Harada T, Iwasaki H, Muta T, Urata S, Sakamoto A, Kohno K, Takase K, Miyamura T, Sawabe T, Asaoku H, Oryoji K, Fujisaki T, Mori Y, Yoshimoto G, Ayano M, Mitoma H, Miyamoto T, Niiro H, Yamamoto H, Oshiro Y, Miyoshi H, Ohshima K, Takeshita M, Akashi K, **Kato K**. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. *Br J Haematol.* 2021; 194: 101-110.
130. Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, **Kato K**, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. *Cancer Sci.* 2021; 112: 2845-2854.
131. Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, **Kato K**, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S. Phase 2 Study of Tazemetostat for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma with EZH2 Mutation in Japan. *Cancer Sci.* 2021; 112: 3627-3635.
132. Yoshimoto G, Mori Y, **Kato K**, Odawara J, Kuriyama T, Ueno T, Obara T, Yurino A, Yoshida S, Ogawa R, Ohno Y, Iwasaki H, Eto T, Akashi K, Miyamoto T. Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation. *Leuk Lymphoma.* 2021; 62: 2939-2948.
133. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators (Collaborators of Japan: **Kato K** et al). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. *N Engl J Med.* 2021; 385: 228-238.
134. Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, Henzan H, Takase K, Yamasaki S, Makiyama J, Moriuchi Y, Choi I, Nakano N, Hiramoto N, **Kato K**, Sato T, Sawayama Y, Kim SW, Inoue Y, Inamoto Y, Fukuda T. A phase I/II multicenter trial of HLA-haploidentical PBSCT with PTCY for aggressive adult T-cell leukemia/lymphoma. *Transplant Cell Ther.* 2021; 27: 928.e1-928.e7.
135. Torisu T, Kawano S, Miyawaki K, Yamamoto H, Ihara Y, Matsuno Y, Torisu K, Sugio T, Sasaki K, Shimakawa T, **Kato K**, Akashi K, Nakamura S, Kitazono T. B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma. *Hematol Oncol.* 2021; 39: 145-147.
136. Yamanaka I, Yamauchi T, Henzan T, Sakoda T, Miyamoto K, Mishima H, Ono H, Koga Y, Nakashima Y, **Kato K**, Miyamoto T, Mizuno S, Ogawa Y, Ohga S, Akashi K, Maeda T, Kunisaki Y. Optimization of lymphapheresis for manufacturing autologous CAR-T cells. *Int J Hematol.* 2021; 114: 449-458.
137. Inoue Y, Nakano N, Fuji S, Eto T, Kawakita T, Suehiro Y, Miyamoto T, Sawayama Y, Uchida N, Kondo T, Kanda J, Atsuta Y, Fukuda T, Yoshimitsu M, **Kato K**; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult

T-cell leukemia-lymphoma. *Bone Marrow Transplant.* 2021; 56: 2964-2974.

138. Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, Choi I, Nakamae H, Nagafuji K, Takase K, Machida S, Takahashi T, Sawayama Y, Kamimura T, **Kato K**, Kawakita T, Ogata M, Sakai R, Shiratori S, Uchimaru K, Inamoto Y, Utsunomiya A, Fukuda T. Improved survival of patients with aggressive ATL by increased use of allo-HCT: A prospective observational study. *Blood Adv.* 2021; 5: 4156-4166.

139. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, **Kato K**, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021; 22: 1403-1415.

140. **Kato K**, Makita S, Goto H, Kanda J, Fujii N, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. *Int J Clin Oncol.* 2022; 27: 213-223.

141. Miyawaki K, **Kato K**, Sugio T, Sasaki K, Miyoshi H, Semba Y, Kikushige Y, Mori Y, Kunisaki Y, Iwasaki H, Miyamoto T, Kuo FC, Aster JC, Ohshima K, Maeda T, Akashi K. A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL. *Blood Adv.* 2021 Oct 12: bloodadvances.2021004618. doi: 10.1182/bloodadvances.2021004618. Epub ahead of print. PMID: 34638128.

142. Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, Hayashi M, Yuda J, Shima T, Odawara J, Takashima S, Kamezaki K, **Kato K**, Miyamoto T, Akashi K, Takenaka K. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2022; 115: 96-106.

143. Imahashi N, Terakura S, Kondo E, **Kato K**, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J, Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J. Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. *Bone Marrow Transplant.* 2021 Nov 24. doi: 10.1038/s41409-021-01525-1. Epub ahead of print. PMID: 34815519.

144. Sugio T, **Kato K**, Yoshida S, Saito N, Kawano I, Henzan H, Miyamoto T, Akashi K, Eto T. Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning. *Japanese Journal of Transplantation and Cellular Therapy* 2022; 11: 64-71.

145. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, **Kato K**, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med.* 2021 Dec 14. doi: 10.1056/NEJMoa2116596. Epub ahead of print. PMID: 34904798.

146. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez

JC, Bachy E, **Kato K**, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*. 2021 Dec 17. doi: 10.1038/s41591-021-01622-0. Epub ahead of print. PMID: 34921238.

147. Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, Miyazaki Y, Ishitsuka K, Sakaida E, Taji H, Wakayama T, Ichinohe T, Fukuda T, Atsuta Y, **Kato K**, Yoshimitsu M. Long-term follow-up of patients with ATL after autologous stem cell transplantation. *Bone Marrow Transplant*. 2022 Jan 23. doi: 10.1038/s41409-021-01412-9. Epub ahead of print. PMID: 35066568.

148. Hori Y, Yamamoto H, Kawatoko S, Nozaki Y, Torisu T, **Kato K**, Koga Y, Miyoshi H, Ohshima K, Tateishi Y, Nakamura S, Kitazono T, Oda Y. Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: A clinicopathological study of 15 cases. *Hum Pathol*. 2022 Jan 3:S0046-8177(21)00218-5. doi: 10.1016/j.humpath.2021.12.010. Epub ahead of print. PMID: 34990621.

149. Uchida M, Murata S, Morikawa H, Yonemitsu H, Ishida S, Suetsugu K, Tsuji T, Watanabe H, Kawashiri T, **Kato K**, Hosohata K, Miyamoto T, Egashira N, Nakamura T, Akashi K, Ieiri I. Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy. *Anticancer Res*. 2022; 42: 2053-2060.

150. Kameda K, Kako S, Kim SW, Usui Y, **Kato K**, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. *Leukemia*. 2022; 36: 1361-1370.

151. Uchida M, Kawai R, Hisamitsu R, Mai S, Ishida S, Watanabe H, Kawashiri T, **Kato K**, Hosohata K, Miyamoto T, Egashira N, Nakamura T, Akashi K, Ieiri I. Evaluation of medication instruction sheets for patients undergoing R-CHOP therapy in non-Hodgkin's lymphoma. *In vivo*. 2022; 36: 1461-1467.

152. Hatakeyama K, Hieda M, Semba Y, Moriyama S, Wang Y, Maeda T, **Kato K**, Miyamoto T, Akashi K, Kikushige Y. TET2 Clonal Hematopoiesis Is Associated With Anthracycline-Induced Cardiotoxicity in Patients With Lymphoma. *JACC CardioOncol*. 2022; 4: 141-143.

153. Mori Y, Harada T, Yoshimoto G, Shima T, Numata A, Jinnouchi F, Yamauchi T, Kikushige Y, Kunisaki Y, **Kato K**, Takenaka K, Akashi K, Miyamoto T. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis. *Int J Hematol*. 2022 May 6. doi: 10.1007/s12185-022-03348-2. Epub ahead of print. PMID: 35524024.

154. Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, **Kato K**, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K. Oral HDAC Inhibitor Tucidinostat (HBI-8000) in Patients with Relapsed or Refractory Adult T-cell Leukemia/Lymphoma: Phase IIb Results. *Cancer Sci*. 2022 May 17. doi: 10.1111/cas.15431. Epub ahead of print. PMID: 35579212.

155. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski SM, Andreadis C, Foley RR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles GA, Schuster SJ, He FC, Maziarz RT, Mayer SA, Makita S,

Kersten MJ, Ghosh M, Wagner-Johnston ND, **Kato K**, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni CL, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv.* 2022; 6: 4816-4820.

156. Sugio T, Baba S, Mori Y, Yoshimoto G, Kamesaki K, Takashima S, Urata S, Shima T, Miyawaki K, Kikushige Y, Kunisaki Y, Numata A, Takenaka K, Iwasaki H, Miyamoto T, Ishigami K, Akashi K, **Kato K**. Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in relapsed and refractory aggressive lymphoma. *Int J Hematol.* 2022 Jun 14. doi: 10.1007/s12185-022-03394-w. Epub ahead of print. PMID: 35701707.

157. Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storrington JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators (Collaborators of Japan: **Kato K** et al). Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. *N Engl J Med.* 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. PMID: 35657079

158. Tsuda M, Hirata A, Tokunaga S, Masuda T, Haji S, Kimura D, Nojiri C, Nakashima Y, Shiratsuchi M, **Kato K**, Miyamoto T, Akashi K, Nakashima N, Ogawa Y. Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia. *Int J Hematol.* 2022 Aug 6. doi: 10.1007/s12185-022-03433-6. Epub ahead of print. PMID: 35932399.

159. Kikushige Y, Miyamoto T, Kochi Y, Semba Y, Ohishi M, Irifune H, Hatakeyama K, Kunisaki Y, Sugio T, Sakoda T, Miyawaki K, **Kato K**, Soga T, Akashi K. Human acute leukemia utilizes branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function. *Blood Adv.* 2022 Aug 31: bloodadvances.2022008242. doi: 10.1182/bloodadvances.2022008242. Epub ahead of print. PMID: 36044390.

160. Goto H, Izutsu K, Ennishi D, Mishima Y, Makita S, **Kato K**, Hanaya M, Hirano S, Narushima K, Teshima T, Nagai H, Ishizawa K. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. *Int J Hematol.* 2022 Sep 15. doi: 10.1007/s12185-022-03450-5. Epub ahead of print. PMID: 36107394.

161. Sakatoku K, Kim SW, Okamura H, Kanaya M, **Kato K**, Yamasaki S, Uchida N, Kobayashi H, Fukuda T, Takayama N, Ishikawa J, Nakazawa H, Sakurai M, Ikeda T, Kondo T, Yoshioka S, Miyamoto T, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. *Ann Hematol.* 2022 Oct 5. doi: 10.1007/s00277-022-04990-w. Epub ahead of print. PMID: 36195679.

162. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, **Kato K**, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia

(CALM): a phase 1, dose-escalation trial. *Lancet Haematol.* 2022 Oct 10:S2352-3026(22)00245-9. doi: 10.1016/S2352-3026(22)00245-9. Epub ahead of print. PMID: 36228643.

163. Matsuda K, Konuma T, Fuse K, Masuko M, Kawamura K, Hirayama M, Uchida N, Ikegame K, Wake A, Eto T, Doki N, Miyakoshi S, Tanaka M, Takahashi S, Onizuka M, **Kato K**, Kimura T, Ichinohe T, Takayama N, Kobayashi H, Nakamae H, Atsuta Y, Kanda J, Yanada M. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study. *Br J Haematol.* 2022 Oct 25. doi: 10.1111/bjh.18530. Epub ahead of print. PMID: 36281887.

164. Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, Ikeda H, Endo M, **Kato K**, Kitano S, Matsumine A, Nagata Y, Kageyama S, Shiraiishi T, Yamada T, Horibe K, Takesako K, Miwa H, Watanabe T, Miyahara Y, Shiku H. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. *BMJ Open.* 2022 Nov 14;12(11):e065109. doi: 10.1136/bmjopen-2022-065109. PMID: 36375974.

165. Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohamad M, Boissel N, Teshima T, **Kato K**, Benjamin R, Balandraud S. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. *Cancer Research Communications* 2022; 2: 1520–1531.

166. **Kato K**, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. *Int J Hematol.* 2022 Nov 18. doi: 10.1007/s12185-022-03494-7. Epub ahead of print. PMID: 36399286.

167. Fukuhara N, **Kato K**, Goto H, Takeshi T, Kawaguchi M, Tokushige K, Akashi K, Teshima T, Harigae H, Schuster SJ, Thieblemont C, Dreyling M, Fowler N. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. *Int J Hematol.* 2022 Nov 21. doi: 10.1007/s12185-022-03481-y. Epub ahead of print. PMID: 36404384.

168. Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Ishitsuka K, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M, **Kato K**. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. *Bone Marrow Transplant.* 2023 Jan 21. doi: 10.1038/s41409-023-01919-3. Epub ahead of print. PMID: 36681773.

169. Belabbas T, Yamada T, Egashira N, Hirota T, Suetsugu K, Mori Y, **Kato K**, Akashi K, Ieiri I. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. *J Infect Chemother.* 2023 Jan 19:S1341-321X(23)00018-1. doi: 10.1016/j.jiac.2023.01.010. Epub ahead of print. PMID: 36682608.

170. Sakoda T, Kikushige Y, Miyamoto T, Irifune H, Harada T, Hatakeyama K, Kunisaki Y, **Kato K**, Akashi K. TIM-3 signaling hijacks the canonical Wnt/ β -catenin pathway to maintain cancer stemness in acute myeloid leukemia. *Blood Adv.* 2023 Feb 6:bloodadvances.2022008405. doi: 10.1182/bloodadvances.2022008405. Epub

ahead of print. PMID: 36745103.

171. Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, Nosaka K, Yoshimitsu M, Yasunaga JI, Kogure Y, Shide K, Miyahara M, Sakamoto T, Akizuki K, Hidaka T, Kubuki Y, Koya J, Kawano N, Yamashita K, Kawano H, Toyama T, Maeda K, Marutsuka K, Imaizumi Y, **Kato K**, Sugio T, Tokunaga M, Tashiro Y, Takaori-Kondo A, Miyazaki Y, Akashi K, Ishitsuka K, Matsuoka M, Ohshima K, Watanabe T, Kitanaka A, Utsunomiya A, Ogawa S, Shimoda K. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma. *Haematologica*. 2023 Feb 16. doi: 10.3324/haematol.2022.281510. Epub ahead of print. PMID: 36794502.

172. Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, **Kato K**, Katayama N, Yamaguchi M. Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. *Cancer Sci*. 2023; 114: 2689-2691.

173. Uchida M, Mochizuki E, Ishida S, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, **Kato K**, Egashira N, Akashi K, Ieiri I. Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia. *In Vivo*. 2023; 37: 924-932.

173. Goto H, Kitawaki T, Fujii N, **Kato K**, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. *Int J Clin Oncol*. 2023; 28: 816-826.

174. Irifune H, Kochi Y, Miyamoto T, Sakoda T, **Kato K**, Kunisaki Y, Akashi K, Kikushige Y. GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia. *Cancer Sci*. 2023 May 17. doi: 10.1111/cas.15835. Epub ahead of print. PMID: 37197765.

175. Inoue Y, Morishima S, **Kato K**, Ito A, Nakano N, Kuriyama T, Kawakita T, Mori Y, Suehiro Y, Itonaga H, Miyazaki Y, Imada K, Tomori S, Kanda J, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma. *Bone Marrow Transplant*. 2023 May 12. doi: 10.1038/s41409-023-02002-7. Epub ahead of print. PMID: 37173417.

176. Nishida R, Eriguchi Y, Miyake N, Nagasaki Y, Yonekawa A, Mori Y, **Kato K**, Akashi K, Shimono N. Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020. *Med Mycol*. 2023 Jun 13:myad056. doi: 10.1093/mmy/myad056. Epub ahead of print. PMID: 37312399.

177. Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, **Kato K**, Egashira N, Akashi K, Ieiri I. Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy. *Anticancer Res*. 2023 Jul;43(7):3321-3329.

【Case report】

1. Imamura R, Inoue H, **Kato K**, Kobayashi S, Tsukamoto H, Nagafuji K, Shimoda K, Nakashima H, Otsuka T, Gondo H, Harada M. Development of rheumatoid arthritis following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2002; 30: 527-9.
2. Numata A, Shimoda K, Gondo H, **Kato K**, Aoki K, Ito Y, Takase K, Asano Y, Okamura T, Niho Y, Harada M. Therapy-related chronic myelogenous leukaemia following autologous stem cell transplantation for Ewing's sarcoma. *Br J Haematol.* 2002; 117: 613-6.
3. Uchino K, Sameshima H, Miyamoto T, Iino T, **Kato K**, Henzan H, Aoki K, Nagafuji K, Gondo H, Harada M. Successful treatment of diffuse large B-cell lymphoma following Waldenstrom's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. *Intern Med.* 2004; 43:131-4.
4. Obama K, Eto T, Tsuruta N, Nagara Y, Okeda A, **Kato K**, Muta T, Gondo H, Shibuya T. Reduced-intensity hematopoietic stem cell transplantation for a patient with myelodysplastic syndrome and chronic obstructive pulmonary disease. *Int J Hematol.* 2004; 80: 470-1.
5. Muta T, Okamura T, Kawamoto M, Ichimiya H, Yamanaka M, Wada Y, Urata M, Kayamori Y, Hamasaki N, **Kato K**, Eto T, Gondo H, Shibuya T. Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency. *Eur J Haematol.* 2005; 75:167-170.
6. Muta T, Kamo M, Gondo H, **Kato K**, Eto T, Shibuya T, Fukuda T, Miyamoto T, Nagafuji K, Ichinohe T, Harada M. Human herpesvirus-6 encephalitis followed by severe acute GVHD after a stem cell transplant from a microchimeric non-inherited maternal antigen (NIMA)-mismatched sibling. *Bone Marrow Transplant.* 2005; 35: 411-3.
7. Yoshida A, Kawano Y, **Kato K**, Yoshida S, Yoshikawa H, Muta T, Eto T, Gondo H, Shibuya T, Ishibashi T, Yamana T. Apoptosis in perforated cornea of a patient with graft-versus-host disease. *Can J Ophthalmol.* 2006; 41: 472-5.
8. Takashima S, Numata A, Miyamoto T, Shirakawa T, Kinoshita R, **Kato K**, Takenaka K, Harada N, Nagafuji K, Taniguchi S, Harada M. Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation. **[in Japanese]** *Rinsho Ketsueki.* 2006; 47: 1372-6.
9. Muta T, **Kato K**, Eto T, Oku S, Nawata R, Takase K, Henzan H, Arima F, Gondo H, Okamura T, Shibuya T. Successful Stem Cell Transplantation without Cryopreservation from a Microchimeric Haploidentical Sibling for Refractory Acute Myeloid Leukemia Complicated with Critical Thrombophlebitis and Cellulitis. *Int J Hematol.* 2007; 85: 85-8.
10. Muta T, **Kato K**, Oku S, Nawata R, Takase K, Henzan H, Arima F, Eto T. Successful mobilization of peripheral blood stem cells in an acute promyelocytic leukemia patient after gemtuzumab ozogamicin. *Bone Marrow Transplant.* 2007; 40: 287-8.
11. **Kato K**, Ohno Y, Mitsuyama S, Toyoshima S, Ito J, Gondo H, Harada M. Long-term remission in a case of anaplastic thyroid carcinoma following local irradiation and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. *Clinical Medicine: Oncology.* 2007; 1: 121-3.

12. Ito Y, Miyamoto T, Chong Y, Aoki T, **Kato K**, Akashi K, Kamimura T. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. *Bone Marrow Transplant.* 2013; 48: 998-9.
13. **Kato K**, Miyamoto T, Numata A, Nakaïke T, Oka H, Yurino A, Kuriyama T, Mori Y, Yamasaki S, Muta T, Takenaka K, Iwasaki H, Teshima T, Akashi K. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma. *Int J Hematol.* 2013; 97: 430-2.
14. Nakaïke T, **Kato K**, Oku S, Hayashi M, Kikushige Y, Kuroiwa M, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Ohshima K, Akashi K. Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. *Int J Hematol.* 2013; 98: 491-5.
15. Yuda J, **Kato K**, Kikushige Y, Ohkusu K, Kiyosuke M, Sakamoto K, Oku S, Miyake N, Kadowaki M, Iino T, Tanimoto K, Takenaka K, Iwasaki H, Miyamoto T, Shimono N, Teshima T, Akashi K. Successful treatment of invasive zygomycosis based on a prompt diagnosis using molecular methods in a patient with acute myelogenous leukemia. *Intern Med.* 2014; 53: 1087-91.
16. Sonoda K, Fukuhara T, Yoshikawa H, Takeda A, Yoshimura T, Akahoshi M, Kusumoto K, Kohno K, **Kato K**, Akashi K, Kohashi K, Aijima S, Namba K, Ishibashi T. A Case Report of Malignant Lymphoma Receiving Infliximab Therapy with Behçet's Disease. *Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc)* 2014; 118: 440-5.
17. Minami M, Shima T, **Kato K**, Yamamoto H, Tsuchihashi K, Oku S, Shimokawa T, Tochigi T, Yoshimoto G, Kamezaki K, Takenaka K, Iwasaki H, Oda Y, Miyamoto T, Akashi K. Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy. *Int J Hematol.* 2015; 102: 244-8.
18. Kuriyama T, **Kato K**, Sakamoto K, Hayashi M, Takashima S, Mori Y, Takenaka K, Iwasaki H, Teshima T, Harada N, Nagafuji K, Miyamoto T, Akashi K. Cord Blood Transplantation Following Reduced-intensity Conditioning for Adult-onset Inherited Hemophagocytic Lymphohistiocytosis. *Intern Med.* 2016; 55: 667-71.
19. Shima T, Kamezaki K, Higashioka K, Takashima S, Yoshimoto G, **Kato K**, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma. *Intern Med.* 2016; 55: 1793-6.
20. Ogata H, Yamamoto Y, Harada T, Nakanishi Y, Okamoto I, Iwama E, **Kato K**, Oda Y. Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. *J Thorac Oncol.* 2017; 12: e46-e47.
21. Sakoda T, Kanamitsu Y, Mori Y, Sasaki K, Yonemitsu E, Nagae K, Yoshimoto G, Kamezaki K, **Kato K**, Takenaka K, Miyamoto T, Furue M, Iwasaki H, Akashi K. Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. *Intern Med.* 2017; 56: 2481-2485.
22. Yanagihara T, Ikematsu Y, **Kato K**, Yonekawa A, Ideishi S, Tochigi T, Sugio T, Miyawaki K, Tanaka K, Harada E, Hamada N, Nakanishi Y. Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma. *Ann Hematol.* 2018; 97: 359-360.
23. Miyake N, Chong Y, Nishida R, Takenaka K, **Kato K**, Miyamoto T, Aono A, Takaki A, Mitarai S, Shimoda S,

- Shimono N, Akashi K. Mycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. *J Infect Chemother*. 2018; 24: 78-81.
24. Sasaki K, Mori Y, Yoshimoto G, Sakoda T, **Kato K**, Inadomi K, Kamezaki K, Takenaka K, Iwasaki H, Maeda T, Miyamoto T, Akashi K. Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation. *Leuk Lymphoma*. 2018; 59: 2005-2008.
25. Minami M, Matsushima T, Mori Y, Ishihara D, Jinnouchi F, Takenaka K, Henzan T, Yoshimoto G, Numata A, **Kato K**, Maeda T, Miyamoto T, Akashi K. Successful rescue transplantation with desensitization procedure after primary graft failure due to donor-specific antibody. *Bone Marrow Transplant*. 2019; 54: 1374-1376.
26. Harada T, Kuriyama T, Nishida R, Yoshimoto G, Mori Y, Imanaga H, Ueno T, Odawara J, Hayashi M, **Kato K**, Takenaka K, Akashi K, Miyamoto T. Successful allogeneic stem cell transplantation in a case with acute myeloid leukemia and invasive *Schizophyllum commune* rhinosinusitis. *J Infect Chemother*. 2020; 26: 506-509.
27. Sato S, Nakahara M, **Kato K**, Moriyama T, Utsumi S, Sasaki K, Shima T, Miyoshi H, Yamamoto H, Furue M. Plasmablastic lymphoma occurring in the vicinity of enterocutaneous fistula in Crohn's disease. *J Dermatol*. 2020; 47: e442-e443.
28. Ishioka K, Oki K, Hirose S, Oguri T, Sasada S, Murata S, Tsuchiya Y, Shigematsu L, Narita H, Adachi T, Fuji Y, Nakamura M, Kitano S, **Kato K**, Ohshima K, Takahashi S. Autopsy of a patient with fatal Epstein-Barr virus-associated encephalitis after treatment with immune checkpoint inhibitors for advanced lung adenocarcinoma: A case report. *Current Problems in Cancer: Case Reports*. 2021; 4: 100108.
29. Moriyama S, Fukata M, Yokoyama T, Ueno S, Nunomura T, Mori Y, **Kato K**, Miyamoto T, Akashi K. Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy. *Front Cardiovasc Med*. 2022 Mar 21;9:848091. doi: 10.3389/fcvm.2022.848091. PMID: 35387436; PMCID: PMC8977736.
30. Takeda A, Sakoda T, Yawata N, **Kato K**, Hasegawa E, Shima T, Hikita S, Yoshitomi K, Takenaka K, Oda Y, Akashi K, Sonoda K. Panuveitis induced by donor-derived CD8⁺ T cells after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia. *American Journal of Ophthalmology Case Reports*, 2022, 101673, ISSN 2451-9936, <https://doi.org/10.1016/j.ajoc.2022.101673>.
31. Taniguchi S, Utsumi S, Kochi Y, Taya Y, Mori Y, Semba YI, Sugio T, Miyawaki K, Kikushige Y, Kunisaki Y, Yoshimoto G, Numata A, **Kato K**, Uchida N, Maeda T, Miyamoto T, Taniguchi S, Akashi K. Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation. *Int J Hematol*. 2022 Sep 22. doi: 10.1007/s12185-022-03458-x. Epub ahead of print. PMID: 36136227
32. Yokoyama S, Koga Y, Anan T, **Kato K**, Ohga S. Pseudo-progressive bone lesion in an infant leukemia after chimeric antigen receptor-T cell therapy. *Pediatr Int*. 2023 Jan;65(1):e15399.

【Review】

1. **Kato K**, Shimoda K. Tyk2-deficient mice **[in Japanese]**. Cellular Molecular Medicine 2003; 2: 693-697.
2. Tokumitsu Y, Matsuura T, Seo M, Taniguchi S, Higuchi M, Kuroiwa M, **Kato K**, Yao T. Graft-versus-host disease **[in Japanese]**. Stomach and Intestine 2003; 38: 601-10.
3. **Kato K**, Eto T, Suzumiya J. The clinical and prognostic classification of adult T-cell leukaemia/lymphoma **[in Japanese]**. Internal Medicine 2005; 95:1680-3.
4. **Kato K**, Harada M. Present status in hematopoietic stem cell transplantation: Peripheral blood stem cell transplantation **[in Japanese]**. Nippon Naika Gakkai Zasshi. 2005; 94: 1281-86.
5. Kanda K, Akiyama N, **Kato K**, Suzuki R. The development of hematopoietic stem cell transplantation **[in Japanese]**. Internal Medicine 2006; 98: 325-36.
6. **Kato K**, Khaled Y, Mineishi S. Reduced-intensity stem cell transplantation for hematological malignancies: Current status and the future. Current Stem Cell Research & Therapy. 2007; 2: 149-62.
7. **Kato K**, Miyamoto T. The role of hematopoietic stem cell transplantation for B cell lymphoma in the Rituximab era **[in Japanese]**. Hematology Frontier 2011; 21: 1477-85.
8. Moriyama T, Esaki M, **Kato K**, Takenaka K, Ichinose R, Kumagae Y, Hirahashi M, Matsumoto T. Hypereosinophilic Syndrome and Eosinophilic Gastrointestinal Disorders. **[in Japanese]**. Stomach and Intestine. 2013; 48: 1921-29.
9. **Kato K**. A report of 12th International Conference on Malignant Lymphoma. **[in Japanese]**. Journal of Molecular Targeted Therapy for Cancer. 2013; 11: 204-6.
10. **Kato K**. Malignant lymphoma and adult T-cell leukemia-lymphoma. Rinsho Ketsueki. **[in Japanese]** 2014; 55: 191-200.
11. **Kato K**. The role of hematopoietic stem cell transplantation for acute myeloid leukemia. **[in Japanese]** Rinsho Ketsueki. 2015; 56: 1950-9.
12. **Kato K**, Akashi K. Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma. Viruses. 2015; 7: 6604-12.
13. **Kato K**. The role of cord blood transplantation for adult T-cell leukemia/lymphoma. **[in Japanese]** Hematology. 2016; 72: 102-6.
14. **Kato K**. The role of hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. **[in Japanese]** Hematology. 2016; 72: 172-8.
15. **Kato K**. Recent progress of BiTE antibody. **[in Japanese]**. Journal of Molecular Targeted Therapy for Cancer. 2016; 14: 98-103.
16. **Kato K**. The role of hematopoietic stem cell transplantation for malignant lymphoma. **[in Japanese]** Internal Medicine. 2016; 117: 1351-4.
17. **Kato K**. Recent advances of monoclonal antibodies in acute lymphoblastic leukemia. **[in Japanese]** The Medical Frontline. 2016; 71: 2064-9.
18. **Kato K**. The role of rituximab maintenance therapy in patients with untreated mantle cell lymphoma. **[in Japanese]** Hematology. 2017; 75: 71-5.

19. **Kato K.** New molecular targeted therapy in malignant lymphoma. [**in Japanese**]. Journal of Molecular Targeted Therapy for Cancer. 2017; 15: 243-9.
20. Utsunomiya A, Ishida T, Ishitsuka K, **Kato K.**, Choi I, Nakano N, Fuji S, Matsuoka K. A consensus meeting for appropriate use of mogamulizumab prior to or after allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma. [**in Japanese**] Hematology. 2017; 75: 544-550.
21. Takeuchi A, **Kato K.**, Akashi K, Eto M. Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy. Int J Urol. 2018; 25: 112-120.
22. **Kato K.** Bruton's tyrosine kinase inhibitor. [**in Japanese**] Hematology Frontier 28: 23-30, 2018
23. **Kato K.**, Kikushige Y, Akashi K. Multistep disease progression of human mature lymphoid malignancies from hematopoietic stem cells. [**in Japanese**] Experimental Medicine 2018; 36: 294-299.
24. **Kato K.** Molecular-targeted therapy and its impact on post-transplant immunity. [**in Japanese**] Rinsho Ketsueki. 2018; 59: 557-565.
25. Fuji S, **Kato K.**, Nakano N, Ishida T, Ishitsuka K, Choi I, Matsuoka KI, Utsunomiya A. Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan. Adv Cell Gene Ther. 2018; 1: e5.
26. **Kato K.** Hematopoietic stem cell transplantation in the era of new molecular-targeted therapies. [**in Japanese**] Rinsho Ketsueki. 2018; 59: 2334-2342.
27. **Kato K.** CAR-T therapy for malignant lymphoma. [**in Japanese**]. Journal of Molecular Targeted Therapy for Cancer. 2018; 16: 316-318.
28. Sakata M, **Kato K.**, Izutsu K. Future perspective of clinical practice and trial in malignant lymphoma. [**in Japanese**] The Medical Frontline 2018; 73: 1411-1423.
29. **Kato K.** Clinical outcomes of Bruton's tyrosine kinase inhibitor in patients with CLL and MCL. [**in Japanese**] The Medical Frontline 2018; 73: 1455-1460.
30. **Kato K.** The role of R-CHOP in patients with untreated follicular lymphoma who have advanced stage and high-tumor burden. [**in Japanese**] Hematology. 2018; 77: 706-712.
31. **Kato K.** The role of immunotherapy in patients with adult T-cell leukemia/lymphoma. [**in Japanese**] Journal of Hematopoietic Cell Transplantation 2019; 8: 9-15.
32. **Kato K.** "Precision Medicine" in malignant lymphoma. CLINCIAN 2019, 671: 214-222.
33. **Kato K.** The role of PET-CT in treatment of patients with malignant lymphoma. [**in Japanese**] Pathology and Clinical Medicine 2019; 37: 215-220.
34. **Kato K.** Epigenetic therapy in hematological malignancy. [**in Japanese**] Clinical Immunology & Allergology 2019; 71: 549-554.
35. **Kato K.** The role of blinatumomab in the treatment of hematological malignancies. [**in Japanese**] Clinical Oncology 2019; 24: 19-26.
36. **Kato K.** The role of rituximab in the treatment of acute lymphoblastic leukemia. [**in Japanese**] Hematology. 2019; 79: 43-48.

37. **Kato K**, Takenaka K. How I treat for relapsed/refractory acute lymphoblastic leukemia? [in Japanese] Japan Medical Journal 2019; 4982: 56.
38. Izutsu K, **Kato K**. Who is a candidate of CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma? . [in Japanese] Japan Medical Journal 2019; 4984: 50.
39. **Kato K**. Hematopoietic stem cell transplantation in the era of new molecular-targeted therapies. [in Japanese] BIO Clinica 34: 605-611, 2019.
40. Sugio T, Miyawaki K, **Kato K**, Sasaki K, Yamada K, Miyamoto T, Ohshima K, Maeda T, Miyoshi H, Akashi K. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. [in Japanese] Hematology. 2019; 78: 531-537.
41. **Kato K**. The role of antibody drug in previously untreated patients with high tumor burden follicular lymphoma. [in Japanese] Hematology. 2020; 80: 176-179.
42. Miyamoto T, **Kato K**. How I treat for CLL. [in Japanese] Japan Medical Journal 2020; 994: 42.
43. Ogata M, Uchida N, Fukuda T, Ikegame K, Kamimura T, Onizuka M, **Kato K**, Kobayashi H, Sasahara Y, Sawa M, Sawada A, Hasegawa D, Masuko M, Miyamoto T, Okamoto S. Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2020; 55: 1004-1013.
44. **Kato K**, Takeuchi A, Akashi K, Eto M. Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application. Front Immunol. 2020; 10: 3138.
45. Tsukasaki K, Marçais A, Nasr R, **Kato K**, Fukuda T, Hermine O, Bazarbachi A. Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. Front Microbiol. 2020; 19: 1207.
46. **Kato K**. Current approach to treat GVHD after allogeneic hematopoietic stem cell transplantation. [in Japanese] Hematology. 2020; 81: 430-435.
47. **Kato K**. Caution when using antibody drugs such as checkpoint inhibitor in patients who receive allogeneic hematopoietic stem cell transplantation. [in Japanese] Hematology. 2020; 81: 800-806.
48. **Kato K**. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). [in Japanese] Journal of clinical and experimental medicine 2021; 277: 927-933.
49. **Kato K**. Treatment approach for relapse of adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. [in Japanese] Rinsho Ketsueki. 2021; 62: 505-511.
50. **Kato K**. How to choose CAR-T therapy in patients with diffuse large B-cell lymphoma. [in Japanese] Hematology. 2021; 82: 762-768.
51. **Kato K**. Recent progress of diagnosis and treatment for peripheral T-cell lymphoma. [in Japanese] The Journal of the Japanese Society of Internal Medicine 2021; 110: 1418-1425.
52. **Kato K**. The role of PET in treatment of patients with malignant lymphoma. [in Japanese] Internal Medicine 2021; 128: 283-287.
53. **Kato K**. Molecular targeted therapy for acute lymphoblastic leukemia. [in Japanese] Journal of clinical and

experimental medicine 2021; 278: 1107-1112.

54. **Kato K.** Recent advances and challenges in CAR-T therapy. [in Japanese] Hematology NAVI 2021; 11: 2-6.

55. **Kato K.** The role of polatuzumab vedotin in treatment of diffuse large B-cell lymphoma. [in Japanese] Hematology. 2022; 84: 272-279.

56. Moriyama T, Mori Y, **Kato K.**, Kawatoko S, Torisu T. Gastrointestinal lesions with hypereosinophilic syndrome and eosinophilic gastrointestinal disease. [in Japanese] Endoscopy Digestiva. 2022; 34: 1425-1430.

57. **Kato K.** Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target? Int J Hematol. 2022 Oct 22. doi: 10.1007/s12185-022-03472-z. Epub ahead of print. PMID: 36273114.

58. **Kato K.** Development of chimeric antigen T-cell therapies for patients with solid tumors. [in Japanese]. Journal of Molecular Targeted Therapy for Cancer. 2022; 20: 54-57.

【Book】

1. **Kato K.** Peripheral blood stem cell transplantation [in Japanese]. Hematopoietic stem cell transplantation (Igakushoin, Tokyo) 2004; 1: 110-120.

2. **Kato K.** Hematopoietic stem cell transplantation for adult T-cell leukaemia/lymphoma [in Japanese]. Case series of hematopoietic stem cell transplantation (Chugaiigakusha, Tokyo) 2006; 1: 37-46.

3. **Kato K.**, Mellacheruvu S, Mineishi S. Stem Cell Transplantation Research Advances; The Evolving Role of Hematopoietic Stem Cell Transplantation in Non-Hodgkin's Lymphoma. Nova Publishers 2008; 1: 71-108.

4. **Kato K.** Memory T cell in immunotherapy. Cancer immunotherapy: Challenge to practical use [in Japanese]. (CMC, Tokyo) 2010; 1: 94-103.

5. **Kato K.** Adult T-cell leukaemia/lymphoma. Practical guide in hematopoietic stem cell transplantation. [in Japanese]. (Nankodo, Tokyo) 2010; 1: 126-131.

6. **Kato K.** Diagnosis and treatment for zygomycosis. Infection in hematopoietic stem cell transplantation [in Japanese]. (Iyaku Journal, Osaka) 2011; 1: 280-282.

7. **Kato K.** The effect of new agents on GVHD [in Japanese]. Clinical and basic studies of GVHD. (Iyaku Journal, Osaka) 2013; 1: 116-23.

8. **Kato K.** Guideline in the Japan Society for Hematopoietic Stem Cell Transplantation, 1st Volume (Iyaku Journal, Osaka). [in Japanese]. 2014 (Editor).

9. **Kato K.** Guideline in the Japan Society for Hematopoietic Stem Cell Transplantation, 2nd Volume (Iyaku Journal, Osaka). [in Japanese]. 2014 (Editor).

10. **Kato K.** Guideline in the Japan Society for Hematopoietic Stem Cell Transplantation, 3rd Volume (Iyaku Journal, Osaka). [in Japanese]. 2014 (Editor).

11. **Kato K.** Anti-coagulant treatment for complications in hematopoietic stem cell transplantation. [in Japanese] Pharma navigator; DIC (Medical review, Tokyo) 2014; 1: 300-307.

12. **Kato K.**, Miyamoto T. Mechanism of action and classification of molecular target drug. [in Japanese] Textbook

of Hematology, Ver2 (Nankodo, Tokyo) 2015; 2: 94-98.

13. **Kato K.** The role of hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. [in Japanese] Evidence Based Hematology 2017-2018 (Chugai Igakusha, Tokyo). 2016 ; 1: 96-103.

14. **Kato K.** Guideline in the Japan Society for Hematopoietic Stem Cell Transplantation, 4th Volume (Iyaku Journal, Osaka). [in Japanese]. 2017 (Editor).

15. **Kato K.** Treatment for relapsed/refractory acute lymphoblastic leukemia. [in Japanese] Evidence Based Hematology 2017-2018 (Chugai Igakusha, Tokyo). 2018; 1: 142-147.

16. **Kato K.** Mechanism of action and classification of molecular target drug. [in Japanese] Textbook of Hematology, Ver3 (Nankodo, Tokyo). 2019; 1: 104-110.

17. **Kato K.** Caution when using antibody drugs such as checkpoint inhibitor in patients who receive allogeneic hematopoietic stem cell transplantation. [in Japanese] Update of treatment in hematological disease 2020-2022. (Nankodo, Tokyo). 2019; 1: 283-286.

18. **Kato K.** Anti-coagulant treatment for complications in hematopoietic stem cell transplantation. [in Japanese] Pharma navigator; DIC Ver2. (Medical review, Tokyo) 2019; 1: 380-387.

19. **Kato K.** How I treat for non-Hodgkin lymphoma. [in Japanese] Recent guide of treatment; (Igakushoin, Tokyo) 2020; 1: 701-704.

20. **Kato K.** Classification of diffuse large B-cell lymphoma. [in Japanese] Hematological malignancy; (Nippon Rinsho, Tokyo) 2020; 1: 529-536.

21. **Kato K.**, Miyawaki K, Sugio T. Immune checkpoint inhibitor for T/NK lymphoma. [in Japanese] Evidence Based Hematology 2021-2022 (Chugai Igakusha, Tokyo). 2020; 1: 337-341.

22. **Kato K.** Peripheral T-cell lymphoma. [in Japanese] Manual of malignant lymphoma. (Nankodo, Tokyo). 2021; 1: 187-192.

23. **Kato K.** Adult T-cell leukemia/lymphoma. [in Japanese] Internal Medicine. (Nankodo, Tokyo). 2021; 127: 931.

24. **Kato K.** Peripheral T-cell lymphoma. [in Japanese] The Journal of the Japan Medical Association. (Japan Medical Association, Tokyo). 2022; 151: 266-268.

25. **Kato K.** Effect of checkpoint inhibitor on clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. [in Japanese] Evidence Based Hematology 2023-2024. (Chugai Igakusha, Tokyo). 2022; 1: 549-554.

26. **Kato K.** Diagnosis by PET. [in Japanese] Update of treatment in hematological disease 2023-2025. (Nankodo, Tokyo). 2022; 1: 271-274.

【Award】

1. **Kato K.** The Fukuoka association of medical sciences (Encouragement award, 2015). The challenge in cord blood transplantation for adult T-cell leukemia/lymphoma.

2. Shimoji S, Hashimoto D, **Kato K.**, Tujigiwa H, Akashi K, Teshima T. Graft-Versus-Host Disease Targets

Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation. ASBMT Best Abstract Awards for Basic Science (Plenary session). 2015 BMT Tandem Meetings, San Diego, USA.

3. Miyawaki K, Sugio T, **Kato K**, Miyoshi H, Sasaki K, Maeda T, Oshima K, Akashi K. Establishment of the novel prognostic model of DLBCL based on microenvironment signature. (Plenary session) The 79th Annual Meeting of the Japanese Society of Hematology (2017), Tokyo, Japan.

4. **Kato K**. Medical Care Education Research Foundation (Clinical Medicine Award, 2019). The development of new treatment for PTCL through the target of microenvironment. in cord blood transplantation for adult T-cell leukemia/lymphoma.

5. Miyawaki K, Sugio T, Sasaki K, **Kato K**, Akashi K. Characterization of the gut immune signature that influences the prognosis of acute gut GVHD. (Plenary session) The 42nd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation. (2020), Tokyo, Japan.

6. Sugio T, Uchida N, Miyawaki K, Mori Y, Yoshimoto G, Numata A, Ogawa R, Kamimura T, Ohno Y, Iwasaki Hiromi, Eto T, Nagafuji K, Miyamoto T, Taniguchi S, Akashi K, **Kato K**. HLA-B supertype mismatch is associated with a higher rate of relapse in cord blood transplantation. The 84th Annual Meeting of the Japanese Society of Hematology (2022), Fukuoka, Japan.

【Guidelines】

Japanese Society for Transplantation and Cellular Therapy:

Graft-versus-host disease (2018 -)

Adult T-cell leukemia/lymphoma (2018 -)

Malignant lymphoma (2019 -)

【Research fund as principal investigator】

1. Clinical trials of hematopoietic stem cell transplantation in the United States of America. Japan Clinical Research Support Unit, Japan. (PI: 4 years, 2006-2009)
2. Development of treatment for GVHD. Takeda Science Foundation, Japan (PI: 3 years, 2010-2012)
3. Adoptive immunotherapy through memory T cell. Japan Leukemia Research Funds, Japan for the Promotion of Science. (PI: 2 years, 2010-2011)
4. New development of treatment for GVHD. Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology, Japan. (PI: 3 years, 2010-2012)
5. Development of treatment for GVHD. Takeda Science Foundation, Japan (PI: 3 years, 2013-2015)
6. The role of memory T cell in development of acute and chronic GVHD. Grant of The Senshin Medical Research Foundation (PI: 1 year, 2012-2012)
7. Genotype of BK virus in hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Grant of The Clinical Research Promotion Foundation (PI: 1 year, 2013-2013)
8. The role of memory T cell in GVHD and GVL. Grant-in-Aid for Scientific Research, Ministry of Education,

Culture, Sports, Science and Technology, Japan. (PI: 3 years, 2013-2015)

9. Development of ovarian protection against allogeneic hematopoietic stem cell transplantation by elucidation of the infertility. Mochida Memorial Foundation for Medical and Pharmaceutical Research, Japan (PI: 1 years, 2013-2013)
10. Development of prognostic stratification and new treatment targeted for lymphoma microenvironment in DLBCL through an absolute quantitative RNA analysis. Japan Agency for Medical Research and Development. (Collaborator: 3 years, 2015-2017)
11. Establishment of allogeneic hematopoietic stem cell transplantation and development of treatment by genome analysis against adult T-cell leukemia. Japan Agency for Medical Research and Development. (Collaborator: 3 year, 2014-2016)
12. Development of new treatment targeted for microenvironment of DLBCL. Japan Leukemia Research Funds, Japan for the Promotion of Science. ¥500,000 [about \$4,500] (PI: 1 year, 2016-2017)
13. Protection of ovary against GVHD. Grant of The Senshin Medical Research Foundation ¥1,000,000 [about \$9,000] (PI: 1 year, 2016-2016)
14. New approach using nanostring system for stratification of lymphoma. Grant of The Shin-Nihon Senshin-Iryo Research Foundation (PI: 1 year, 2016-2016)
15. Development of new treatment targeted for microenvironment of B-cell lymphoma. Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology, Japan. (PI: 3 years, 2016-2018)
16. Relationship between tumor mutation and microenvironment in diffuse large B-cell lymphoma. Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology, Japan. (PI: 3 years, 2019-2021)
17. Relationship between tumor mutation and microenvironment in Peripheral T-cell lymphoma. Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology, Japan. (PI: 3 years, 2022-2024)

【Clinical trial as principal investigator】

1. PET guided therapy of DLBCL with or without high dose chemotherapy followed by ASCT (JSCT-NHL10, 2010-)
2. Prospective cohort study of low-grade lymphoma in Fukuoka lymphoma study group (FLSG). (2011-)
3. Prospective observational study of the treatment and prognosis in patients with relapsed ATLL after allo-HSCT (JSCT-ATLL12, 2012-)
4. Prospective cohort study of the prognosis in patients with relapsed FL treated with Rituximab/bendamustine (W-JHS NHL01, 2014-)
5. Clinical research on sequential combination therapy with CHOP and mogamulizumab in patients with untreated primary adult T cell leukemia-lymphoma (FBMTG MOG16, 2016-)
6. Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial (W-JHS NHL02, 2018-)
7. A prospective observational study of polatuzumab vedotin with R-CHP treatment as standard of care in

previously untreated diffuse large B-cell lymphoma (POLASTAR study: W-JHS NHL03, 2022-)

8. Real world data of lisocabtagene maraleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. (JSCT CART23 study, 2022-)